Abstract
Background and ImportanceLebrikizumab, tralokinumab and dupilumab are anti-interleukin-13 monoclonal antibody used as therapy in patients with moderate to severe atopic dermatitis (msAD). There are no direct comparisons among them.Aim and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have